Navigation Links
Merrimack Pharmaceuticals Promotes Ulrik B. Nielsen, Ph.D. to Chief Scientific Officer and Edward J. Stewart to Senior Vice President of Business Development
Date:3/9/2009

CAMBRIDGE, Mass., March 9 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc., a privately held biotechnology company focused on the discovery and development of novel treatments for cancer and autoimmune disease, today announced that Ulrik B. Nielsen has been promoted to Senior Vice President and Chief Scientific Officer and Edward (Tad) J. Stewart to Senior Vice President of Business Development.

"Ulrik and Tad have both played critical roles in building Merrimack into the fully integrated and clinically diversified research and development company that we are today," said Robert Mulroy, President and CEO of Merrimack. "Merrimack is at the forefront of the systems biology field with a robust pipeline of biologics in large part due to the dedication and innovation that Ulrik brings to building integrated, predictive medicines through the use of Network Biology and Tad's expertise in establishing the collaborations and intellectual property foundation to drive our business."

In his new position, Dr. Nielsen, a founder of Merrimack who has been with the Company since inception, continues to be responsible for the strategic direction of the Company's research, early stage pipeline products, new project ideas and discovering and encouraging innovative techniques of integrating the Network Biology platform into therapeutic development from discovery stage through to the clinic. Prior to joining Merrimack, Dr. Nielsen was a post-doctoral fellow in Dr. Peter Sorger's laboratory at the Massachusetts Institute of Technology, where he researched the interface among biology, engineering, and computational biology. Dr. Nielsen received his Ph.D. from the University of Copenhagen in molecular biology and received Master's and Bachelor's degrees in biochemistry from the University of Copenhagen.

Mr. Stewart's, who has been with the Company sinc
'/>"/>

SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Merrimack Pharmaceuticals Announces the Addition of Robert Gay to its Board of Directors
2. Merrimack Pharmaceuticals Raises $60 Million in Private Financing
3. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...v.25/PRNewswire/--Reportlinker.comannouncesthatane..., BrazilBioethanolMarketAnalysisandForecaststo2...razil-Bioethanol-Market-Analysis-and-Forecasts-to-...Forecaststo2013 ,, Summary ,, Thereportpro...anolmarketandtheBrazilbioethanolmarketinparticular...
(Date:11/24/2009)... The New York investment bank KTA Capital,s...greed an AU$6.7 mil convertible note private place...te placement was arranged by KTA Capital as Neuren... New York (PRWEB) November 23, 2...A Capital, LLC ("KTA Capital") has annou...
(Date:11/24/2009)... Health care employment grew by 29,000 jo...to show consistent growth during the U.S. recessio... in trouble, and health systems are coming closer ...ad of just administrators. , ...yment continued growing in October despite the she...
(Date:11/24/2009)...v.24/PRNewswire/--BlueMarbleEnergyCorp.announcedto...ority(OPDA)wererecentlyawarded$2millionbyWashingto...inaprivate/publicpartnershiptoconstructthestate,sf...,WA. ,, "Thisinvestmentwillsignificantlyspeedth...stoLincolnCounty,"saidBlueMarbleEnergyCEOKellyOgil...
Breaking Biology Technology:Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 2Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 3Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 4Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 5Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 6Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 7Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 8Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 9KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 4Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2
...d.,(TASE: ITGI) announced today the first commerci...ardium Covered Stent (PCS) in the UK, Over and Un... tissue,designed to set a barrier between the coro...ed for situations such as degenerated Saphenous Ve...first Over and Under(R) PCS commercial implantatio...
...affect patient response to ...2 Roche and DxS Ltd. have,signed an exclusive dis...Mutation Test and TheraScreen EGFR 29 Mutation Tes...her clinically relevant factors, to aid,doctors in...rom a specific,cancer therapy based on their mutat...
...s,area within SAFC(R), a member of the Sigma-Aldri...oduction of the OM700, a bubbler that offers,custo... precursor delivery,for larger lot sizes, enabling...creased safety controls., The OM700 offers reliab...tive organometallic precursors, such as trimethylg...
Other Biology Technology:Over and Under(R) Pericardium Covered Stent is now in use in England and Proves Great Deliverability 2Roche Signs Exclusive Distribution Deal with DxS for K-RAS and EGFR Cancer Mutation Tests 2Roche Signs Exclusive Distribution Deal with DxS for K-RAS and EGFR Cancer Mutation Tests 3SAFC Hitech Introduces Large Scale Bubbler for Compound Semiconductor Production 2SAFC Hitech Introduces Large Scale Bubbler for Compound Semiconductor Production 3
(Date:11/26/2009)...t in eight European countries has shown that closi...andemic could have a significant role in reducing ...pen access journal BMC Infectious Diseases compa... weekends/holidays, finding that they were reduced...t and Antwerp University, Belgium, led a team of E...
(Date:11/25/2009)...produced in the stomach, may be used to boost resi... disease, Yale School of Medicine researchers repo...Journal of Neuroscience . , Parkinson,s disease ... an area of the midbrain known as the substantia n.... Reduced production of dopamine in late-stage Pa...
(Date:11/25/2009)...a lifetime, the heart pumps some 250 million liter...is, the muscle fibers of the heart have to be extr...lfgang Rottbauer, vice chair of the Department of ...airman: Prof. Dr. H. A. Katus), has discovered a p...e smallest muscular unit, the sarcomere. In cooper...
Breaking Biology News(10 mins):School closure could reduce swine flu transmission by 21 percent 2Hormone ghrelin can boost resistance to Parkinson's disease 2New genetic cause of cardiac failure discovered 2SYGNIS to Present at the 11th Rodman 26 Renshaw Annual Global Investment Conference 56338 1SYGNIS to Present at the 11th Rodman 26 Renshaw Annual Global Investment Conference 56338 2OAG Releases Prototype for Pandemic Disease Planning and Management 56336 1OAG Releases Prototype for Pandemic Disease Planning and Management 56336 2OAG Releases Prototype for Pandemic Disease Planning and Management 56336 3Restorative Therapies Inc Receives FDA Clearance for RT300 Enhancements 56333 1Restorative Therapies Inc Receives FDA Clearance for RT300 Enhancements 56333 2Restorative Therapies Inc Receives FDA Clearance for RT300 Enhancements 56333 3
... Department of Energys Office of Science today rel...publication, Facilities for the Future of Science:...made significant progress in deploying the scienti...tes needs to capture world scientific leadership, ...partments missions. , When it was published four ...
...One of the World,s Leading Software ..., Oct. 10 (OTC Bulletin,Board: CICI) Communicatio...lier of electronic signature solutions for busines... the recognized leader in biometric signature,veri...rd time in Software,Magazine,s Software 500 rankin...
...angladesh finds that folic acid supplements can dr...ls chronically exposed to arsenic-contaminated dri...aturally present in some soils and water. Arsenic...icant public health problem in at least 70 countri...o parts of the United States. Chronic arsenic exp...
Other Biology News:DOE publishes update of plan: 'Facilities for the Future of Science: A 20-Year Outlook' 2DOE publishes update of plan: 'Facilities for the Future of Science: A 20-Year Outlook' 3DOE publishes update of plan: 'Facilities for the Future of Science: A 20-Year Outlook' 4DOE publishes update of plan: 'Facilities for the Future of Science: A 20-Year Outlook' 5CIC Again Named to Software Magazine's Annual Prestigious Software 500 List 2CIC Again Named to Software Magazine's Annual Prestigious Software 500 List 3Folic acid lowers blood arsenic levels in Bangladesh 2Folic acid lowers blood arsenic levels in Bangladesh 3
Mouse Anti-Human XPC Polyclonal Antibody, Unconjugated from ABR-Affinity BioReagents
Rabbit Anti-Lck, phospho (Tyr192) Polyclonal Antibody, Unconjugated from Abcam
Anti-7H6 Antigen (tight-junction associated protein antigen) Monoclonal Antibody, Unconjugated, Clone 7H6 from Cell Sciences
Goat Anti-Ephrin B2 Polyclonal Antibody, Unconjugated from Abcam
Biology Products: